2 results
Approved WMOWill not start
PrimairTo determine the MTD and/or RP2D of oral twice daily (BID) BEZ235 in combination with trastuzumab in patients with HER2-positive breast cancerSecondairTo assess the preliminary activity of the combinationTo assess the safety and tolerability…
Approved WMOCompleted
Primary: To explore the effect of the H1-antagonist hydroxyzine 50 mg on motor response, attention and impulsivity, using a test battery and task manipulations. Secondary: To explore the effect of the H1-antagonist hydroxyzine 50 mg on…